Study objective-The aim was to demonstrate the benefits of breast cancer screening on mortality.
odds ratio 0'52, with a stronger effect in older women and no evidence of confounding; (2) risk ratio of dying from breast cancer for women in the response group was the same as the odds ratio, 0 52; (3) breast cancer death rate after the start of the project was nearly 20% lower than before the project started; after correcting for women who could not have benefited from screening the reduction was 33%; (4) a rise in breast cancer mortality in birth cohort [1911] [1912] [1913] [1914] [1915] [1916] [1917] [1918] [1919] [1920] [1921] [1922] [1923] [1924] [1925] seen in other large cities without a screening programme due to aging of the cohort was not seen in the city ofUtrecht; (5) mortality reduction followed the screening activity with a time lag of approximately 5 years.
Conclusions-Early diagnosis of breast cancer by mammography reduces breast cancer mortality in women 50-64 years old at intake; different approaches to the evaluation of the project give different estimates ofthe screening effect, making clear that the effect depends on the intensity of the programme.
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The first effects on mortality from breast cancer of a mass screening project in the city of Utrecht using both physical examination and (xero)mammography were published in 1984.' The project was called the DOM project, which in Dutch signifies "Diagnostisch Onderzoek (= investigation) Mammacarcinoom". It has a double meaning, because Utrecht is sometimes called the DOM city for its medieval cathedral. As the DOM project used a non-randomised design, we measured the effects on mortality from breast cancer by means of a case controlled study.
In the case-control study, a case was defined as a breast cancer death in a woman born between 1911 and 1925, diagnosis and death occurring after the start of the project. For each case, three controls were selected at random from the local population registries, matched for year of birth. For both the case and the corresponding controls, the screening history was ascertained from the records of the DOM project. The screening history was taken for the time up to and including the date of diagnosis of the case, ie, a "restricted period" compared with the period of the total screening programme. A protective effect of screening against dying from breast cancer was found (odds ratio 0 30, 95% confidence interval 0 For that reason, data about height and weight of the cases and controls in the period 1975-1983 were collected. In the various hospitals and in the screening centre, weights and heights were available for approximately 65% of both groups. Table V shows that there were no great Evaluation of the DOM project shows a "healthy screenee effect" with regard to overall mortality. 6 The question arises as to whether this I ).
Five year moving averages were calculated for the numbers of examinations so that these can be compared with the reduction in breast cancer mortality, the latter being expressed as the difference between the mortality rate of the 17 cities and that of the city of Utrecht. Both are depicted in fig 3. The mortality reduction parallels the screening activity with a time lag of approximately five years, increasing at first and subsequently decreasing.
Discussion
In this paper, further evidence is presented for the protective effect of breast cancer screening, not only by extending the case-control study and searching for confounding variables and bias in this study, but also by looking at breast cancer mortality rates in the cohort targeted for screening and at the corresponding rates in comparable groups in the rest of The Netherlands.
So far no evidence has emerged that the effect demonstrated in the case-control study was caused by confounding. Moreover, bias free ways of analysing the data, ie, calculating relative risk from the mortality rates in the total screened and unscreened groups, support this conclusion, as does the comparison of breast cancer mortality after the start of the DOM project with the previous rate, showing a 33% reduction in women eligible for screening. Given 72% original compliance, this converts into a 460% reduction among women screened, very close to this case-control result, thus confirming the lack of bias in the case-control comparison.
Analysis of breast cancer mortality reveals a reduction in the cohort targeted for screening, not only when compared with the mortality before the start of the project, but also when compared with that in other large cities without screening programmes. The fact that the effect calculated in this way is smaller than that in the case-control approach can be explained by diluting factors, ie, factors which mask the real effect. There are several such factors: (1) women with breast cancer diagnosed before the start of the project dying from breast cancer during the period under study; (2) women with breast cancer diagnosed before they received the invitation to participate-as it 
